Resultados de la búsqueda 241-250 of 19138 for Two-phase

  1. Neurología - Ensayos clínicos - Mayo Clinic

    This phase II trial tests whether an exercise ... The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech ...

  2. Oncología (médica) - Ensayos clínicos

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  3. Hematología - Ensayos clínicos

    ... phase II dose (RP2D of APG2575 in combination ... Patients will be randomized 1:1 into the two arms. ... 2-6: 500 mg/m2). Patients randomized to B+R will ...

  4. Neurología - Ensayos clínicos

    The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in recurrent glioblastoma as ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    In the phase II part, to evaluate the preliminary antitumor activity of two ... This is a Phase 2 global, multi-center, open-label study to assess the ...

  6. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...

  7. Oncología (médica) - Ensayos clínicos

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  9. Oncología (médica) - Ensayos clínicos

    ... 2 (cohort expansion in two cohorts). Phase 1/2 Study Of MRTX1719 In Solid Tumors With MTAP Deletion. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...